Pacira BioSciences is at the forefront of innovation in pain management, focusing on non-opioid solutions to address the challenges associated with opioid overreliance in postsurgical care. The company utilizes proprietary multivesicular liposome (pMVL) technology, which allows for the encapsulation of drugs without altering their molecular structure, enabling controlled release over a specified duration. This technology is exemplified in their flagship product, EXPAREL® (bupivacaine liposome injectable suspension), which is designed to provide long-lasting local analgesia when administered at the time of surgery. By effectively numbing the surgical site, EXPAREL aims to reduce or eliminate the need for opioids in managing acute postsurgical pain, thereby minimizing the risk of opioid-related adverse events.

In addition to EXPAREL, Pacira offers other innovative products such as the iovera° system and ZILRETTA® (triamcinolone acetonide extended-release injectable suspension). The iovera° system employs a handheld cryoanalgesia device that delivers controlled doses of cold to specific nerves, interrupting pain signal transmission and providing immediate pain relief that can last for several months. ZILRETTA, on the other hand, is the first approved treatment for osteoarthritis knee pain that utilizes extended-release microsphere technology, offering a non-opioid option for significant pain relief. Together, these technologies reflect Pacira's commitment to advancing patient care through safer and more effective pain management solutions.

United States

Pacira BioSciences Inc. is a leading provider of non-opioid pain management and regenerative health solutions. We are dedicated to offering patients—and the clinicians who treat them—cutting-edge therapies to treat pain with the potential to reduce or eliminate the need for opioids. 

Founded in 2006 and headquartered in Tampa, FL, Pacira has offices in Parsippany, NJ as well as San Diego, CA. With more than 700 employees who share a passion for delivering improved patient care and reducing the need for opioids, Pacira is here to challenge and transform the way we think about – and treat – pain. 

We are committed to providing solutions that address unmet medical need and improve clinical results, and empowering patients and healthcare providers to choose non-opioid options. Our non-opioid product portfolio is aimed at opioid minimization, long-lasting pain control, and enhanced recovery. 

Find out why we aim for change at Pacira.com/commitments

Pathological Conditions

Pacira BioSciences

Post operative acute pain

Local anesthetics block the generation and the conduction of nerve impulses presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.
<a href="https://www.exparel.com/hcp/EXPAREL_Package_Insert_CBE-15_Jan_2021.pdf">Source</a>

Exparel (bupivacaine liposome)

Osteoarthritis pain

Triamcinolone acetonide is a corticosteroid with anti-inflammatory and immunomodulating properties. It binds to and activates the glucocorticoid receptor, leading to activation of anti-inflammatory transcription factors such as lipocortins and inhibition of inflammatory transduction pathways by blocking the release of arachidonic acid and preventing the synthesis of prostaglandins and leukotrienes.
<ul class="font_7">
 <li>source: FDA Label (<a href="http://Triamcinolone acetonide is a corticosteroid with anti-inflammatory and immunomodulating properties. It binds to and activates the glucocorticoid receptor, leading to activation of anti-inflammatory transcription factors such as lipocortins and inhibition of inflammatory transduction pathways by blocking the release of arachidonic acid and preventing the synthesis of prostaglandins and leukotrienes.">section 12.1</a>)</li>
</ul>

ZILRETTA® (triamcinolone acetonide) 

Exparel (bupivacaine liposome) 

Knee osteoarthritis

Osteoarthritis

<a href="https://www.globenewswire.com/Tracker?data=eNSE20kmk1pMWXSTcpnxPX3knt-ZAMQj8CuoRJEnwS9CJNvb-aeGCys08_Sw7occ8GVlQnRwYKoYqd1Rm0K95rMB0wJtmBA2cUv0fMsyYo5yLOkpY400H2m7Eq-j304nNthhcPXDDP-HpXVhfRfUpJS45uM8mwlKTcZ8uZnZgpP6O4ER01gvhj5rBK5gRFCF8Fyj9gBLW8R7nqTJAbq3QRGdCID2P8ckAw8uPFkX5HOaKugKuWxu0mU9WvZnhZ5w" rel="nofollow" target="_blank">FX201</a> is an investigational gene therapy that utilizes a helper-dependent &nbsp;adenovirus (HDAd) vector devoid of all viral genes that carries a coding &nbsp;sequence for an anti-inflammatory protein called interleukin-1 receptor &nbsp;antagonist (IL-1Ra) under the control of an inflammation-responsive &nbsp;promoter. FX201 is injected directly into the joint space (also termed &nbsp;the intra-articular space) and is intended to deliver as-needed &nbsp;anti-inflammatory activity to joint tissues, with the goal of providing &nbsp;at least 6 to 12 months of meaningful pain relief and functional &nbsp;improvement following a single injection with the possibility of slowing &nbsp;disease progression.
<a href="https://ir.flexiontherapeutics.com/news-releases/news-release-details/flexion-therapeutics-reports-first-quarter-2021-financial">Source</a>
Gene therapy

PCRX-201 (enekinragene inzadenovec)

Pain

<a href="https://www.globenewswire.com/Tracker?data=hmj-yN3wsaA-Plu2bnlWv5Mk8McFN_KnmsvpDYgQBBVe-FAKTGAMRchs_z4oW8qqdY461Xch8wljTbg4NuXQgfpk9H2t-5fa4MaV9ZVXBImM_S8Z3Kab3oJqx8O4tYMqEYpT4-G21P39Wtz_wigtKaTaUCA1WLQT7N5JL_6Vjx5PMgOCHBAn3W9NMb1_gffLroAhNeU3EuiJ4lTsDpXgWX0Ro7XaUr0KrF9diHyOIh2EdsmcTFWHdQOALPF35CAf" rel="nofollow" target="_blank">FX301</a> is an investigational locally administered NaV1.7 inhibitor known as &nbsp;funapide, formulated for extended release in a thermosensitive hydrogel. &nbsp;The initial development of FX301 is intended to support administration &nbsp;as a peripheral analgesic nerve block for control of post-operative &nbsp;pain. Flexion believes FX301 has the potential to provide effective pain &nbsp;relief for at least three to five days while preserving motor function.
<a href="https://ir.flexiontherapeutics.com/news-releases/news-release-details/flexion-therapeutics-reports-first-quarter-2021-financial">Source</a>

Pacira BioSciences

Company Details